Hylase vascular therapy

Treatment approach for atherosclerosis

Atherosclerosis is one of the most common causes of myocardial infarction and stroke – especially in people with diabetes or severe vascular disease. Hylase vascular therapy is an experimental approach that aims to support damaged blood vessels and their function.

The treatment is based on the enzyme hyaluronidase and is used in the practice of Dr. med. Alexander Hierl in Munich. It is intended for patients with advanced vascular calcification, severe high blood pressure or serious diabetes complications in whom conventional methods are no longer sufficient.

What does the therapy aim to do?

Hylase vascular therapy aims to make altered vessel walls more elastic and more permeable. The infusion treatment is intended to support vessel-wall structure, blood flow and the body’s own repair processes, so that deposits inside the vessel can be broken down more effectively.

• Improvement of vessel elasticity and reduction of vessel stiffness
• Support of blood flow in affected areas
• Reduction of the risk of further narrowings
• Support of wound healing in severe vascular disease

Who may it be suitable for?

The therapy is intended for patients with advanced atherosclerosis or vascular calcification who have not improved sufficiently with conventional measures. It may also be considered in marked high blood pressure or diabetic foot syndrome.

How does Hylase treatment proceed?

Hylase treatment consists of several infusions over about two to three weeks. Beforehand, a detailed history, physical examination and laboratory diagnostics are performed to assess suitability. During treatment the patient is monitored closely, especially regarding blood pressure and tolerability.

What side effects can occur?

Hylase vascular therapy is generally described as well tolerated. Relevant side effects have not been observed in this practice so far. As with any therapy, uncommon reactions can occur – for example skin reactions, local pain or swelling at the infusion site, or brief circulatory changes.

An individual assessment by the treating physician is required, especially in patients with known sensitivity to hyaluronidase or infusion therapies.